In cells derived from facioscapulohumeral muscular dystrophy (FSHD) patients, CRISPR can be used to ablate expression of the toxic DUX4 protein by deleting specific genomic sequences [90] or suppressing DUX4-encoding transcripts [91]. This evidence concerns the gene DUX4 and facioscapulohumeral muscular dystrophy.